Regulus Files for Initial Public Offering | GenomeWeb

Regulus Therapeutics, the microRNA drug joint venture between Alnylam Pharmaceuticals and Isis Pharmaceuticals, has filed with US regulators to begin selling its shares on the public market.

The move to float its shares has been expected for some time, as Regulus in 2010 began looking to fill positions with duties related to the activities of a public company (GSN 9/23/2010).

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Genome Research this week: transcriptomic analysis of the Venus flytrap, SMASH approach for CNV analysis, and more.

A Caltech professor wins the Millennium Technology Prize that lauds technological advances that improve human life.

San Diego's biotech scene has a dearth of executives who are women, Stat News reports.

Some 90 percent of respondents to a Nature survey say there is a research reproducibility crisis.